Acurx Pharmaceuticals Inc
Research Acurx Pharmaceuticals Inc (ACXP) on Bullrun: market cap USD 4.78M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerACXP
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 4.78M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 7.50M
- Free cash flow-USD 1.41M
Valuation Snapshot
latest market cap is USD 4.78M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 7.97M | -USD 6.79M | n/a | -5.32 | USD 7.56M | n/a | USD 5.27M |
| FY2024 | USD 0 | -USD 14.10M | -USD 10.38M | n/a | -17.45 | USD 3.71M | n/a | USD 615.12K |
| FY2023 | n/a | -USD 14.58M | n/a | n/a | -1.15 | USD 7.47M | n/a | USD 4.67M |
| FY2022 | n/a | -USD 12.09M | n/a | n/a | -1.12 | USD 9.11M | n/a | USD 7.32M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 4.78M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 5.85M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 13.86M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 52.73M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 46.14M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 44.14M | n/a | n/a | n/a |
About Acurx Pharmaceuticals Inc
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Acurx Pharmaceuticals Inc's market cap?
Acurx Pharmaceuticals Inc's market capitalization is USD 4.78M.
What does Acurx Pharmaceuticals Inc do?
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.